Travere Therapeutics (17R) AI Stock Analysis

2 Followers

Travere Therapeutics

(Berlin:17R)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue Scale and Gross MarginRapid revenue expansion and consistently exceptional gross margins indicate strong product economics and growing commercial reach. This combination can support reinvestment in the pipeline and commercialization while providing a durable foundation for improving operating leverage over the next several quarters.

Negative Factors

High Leverage and Thin EquitySharp debt growth alongside substantial equity erosion leaves Travere with a very thin capital cushion and elevated leverage. This reduces financial flexibility if operating performance weakens and can constrain the company's ability to fund growth, absorb volatility, or allocate capital without balance-sheet pressure.

Travere Therapeutics (17R) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.00B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -33.4
Beta (1Y): 1.42
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 497
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Travere Therapeutics Business Overview & Revenue Model

Company Description

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease...

Travere Therapeutics Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 25, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by record FILSPARI sales, approximately 120% year-over-year product growth, strong demand and persistence across IgA nephropathy and FSGS, encouraging clinical data, and continued pipeline and patent progress. The main challenges were expected fourth-quarter inventory normalization, a slight sequential decline in IgA nephropathy demand, anticipated gross-to-net pressure, substantial licensing-related expense, and the upcoming CEO transition. Positive operating momentum and pipeline progress significantly outweighed the stated headwinds.

Positive Updates

FILSPARI Quarterly Sales Surpassed $200 Million

Third-quarter FILSPARI U.S. net product sales reached $200.2 million, representing approximately 120% year-over-year growth. Total U.S. net product sales were $220.2 million, and total revenue was $224.6 million.

Negative Updates

Fourth-Quarter Sales Headwind From Specialty Pharmacy Inventory

Orders from specialty pharmacy partners increased inventory above historical levels and contributed approximately $8 million to third-quarter FILSPARI net sales. The company expects fourth-quarter net sales to be reduced by approximately the same amount as specialty pharmacies dispense existing stock to return to normal inventory levels.

Company Guidance

Management reiterated confidence in achieving or exceeding more than $3 billion in annual FILSPARI sales by 2033, with strong demand in both indications and expectations for an accelerated adoption curve and then a sustained demand moving forward; fourth quarter FILSPARI net sales are expected to be reduced by approximately $8 million, while full year gross to net discounts for FILSPARI are expected to be in the mid-20 percent range. Management expects top line results from the phase 3 HARMONY study in the second half of 2027, is on track to initiate SPARSLITE later this year and anticipates sharing data in 2027, plans to submit a U.S. IND for Civorebrutinib by year-end, and said the U.S. IND is planned for this quarter; no guidance was provided on patient start forms.

Travere Therapeutics Risk Analysis

Travere Therapeutics disclosed 61 risk factors in its most recent earnings report. Travere Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Our ability to realize the anticipated benefits of in-licensed products and collaboration arrangements depends on several factors, many of which are outside of our control.*Q2, 2026

2.If we fail to establish or maintain successful collaborations or licensing arrangements, including cross-border collaborations, our business could be adversely affected.*Q2, 2026

Travere Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:17R against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	84Outperform	$2.18B	6.84	51.92%	―	21.04%	312.89%
IMVT	53Neutral	$7.39B	-14.47	-63.01%	―	―	9.82%
VERA	53Neutral	$2.17B	-5.17	-90.03%	―	―	-48.21%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.25B	9.50	-109.40%	―	―	―
IONS	42Neutral	$4.69B	-8.53	-120.44%	―	-0.79%	-106.48%

* Healthcare Sector Average

Performance Comparison

DE:17R and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:17R	Travere Therapeutics, Inc.	33.00	3.20	10.74%
IONS	Ionis Pharmaceuticals Inc.	28.33	-41.51	-59.44%
OMER	Omeros Corporation	18.15	11.87	189.01%
AUPH	Aurinia Pharmaceuticals	16.21	0.99	6.50%
IMVT	Immunovant, Inc.	37.04	14.22	62.31%
VERA	Vera Therapeutics, Inc.	30.48	2.11	7.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Travere Therapeutics AI Stock Analysis